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Although COPD is a major disease worldwide there is a perplexing current uncertainty about
the nature of this disease. COPD is characterized at onset and prevalently by the involvement
of the lungs and bronchi, but as the disease evolves abnormalities develop in other organs and
systems and the question arises: what is the pathogenesis of these respiratory and systemic
impairments? Are the alterations that occur outside the respiratory system in the course of
COPD a direct consequence of the lung pathology or is the lung simply the local expression
of a pathological event whose origin lies in the organism as a whole? To tease out this issue,
the Expert Opinion Consensus/Dissensus Seminar ‘‘COPD is/is not a systemic disease?’’ took
place in Venice, on 13e14 November 2008. The Seminar was conceived and organized by
the Italian Interdisciplinary Association for Research in Lung Disease, AIMAR. Top international
opinion leaders in the respiratory field were invited to participate, the aim being to bring
together sustainers of the two sides in a format allowing the best opportunity for an in-depth
debate. Over the two days, different aspects of the issue ‘upstream’ (pathophysiology and322 836718; fax: þ39 0322 869950.
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COPD is not a systemic disease 1271biology) and ‘downstream’ (treatment and outcome assessment) were discussed. The general
consensus that emerged, based on the still limited evidence available, was that COPD begins as
a local inflammation in the lungs and this leads e through differentiated pathways yet to be
fully clarified e to systemic consequences.
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cause of mortality in industrialized countries, 6th in low-
middle income countries) with a steadily increasing preva-
lence,1,2,3 and COPD-driven costs are becoming a major
burden for national health services and private health
insurance companies alike, there is a perplexing current
uncertainty about the nature of this disease. The complex
variety of phenotypes and lack of an ideal biomarker that
would simplify diagnosis are just two aspects of this confu-
sion.4 Even the concept of the disease itself as defined by
international guidelines has recently come under fire.5,6,7
COPD is characterized at onset and prevalently by the
involvement of the lungs and bronchi, but as the disease
evolves abnormalities develop in many other organs and
systems e e.g. renal and hormonal abnormalities in type-B
COPD (with chronic bronchitis); muscle wasting, osteopo-
rosis, anemia and reduction in circulating bone marrow
progenitors in type-A COPD (with emphysema) e and a key
question arises: what is the pathogenesis of these respira-
tory and systemic impairments? Are the pathological alter-
ations that occur outside the respiratory system in the
course of COPD a direct consequence of the lung pathology
or is the lung simply the local expression of a pathological
event whose origin lies in the organism as a whole (and about
the nature and mechanisms of which we as yet have only
partial knowledge)?8,9
To try to tease out this issue, which has obviously
important implications, in particular for treatment, the
Expert Opinion Consensus/Dissensus Seminar ‘‘COPD is/is
not a systemic disease?’’ took place recently in Venice, on
13e14 November 2008. The Seminar was conceived and
organized by AIMAR (Italian Interdisciplinary Association for
Research in Lung Disease) with the endorsement of the two
other leading Italian national Societies for Respiratory
Medicine, AIPO and SIMeR. Top international opinion
leaders in the respiratory field were invited to attend as
speakers, chairpersons and discussants, the aim being to
bring together sustainers of the two sides in a format that
would allow the best opportunity for discussion and debate
(two 15-min interventions ‘pro’ and ‘con’ on each subject
followed by 30 min of feedback from the floor; then
a further period of discussion in the afternoon, with the aimto try and reach a final consensus or dissensus on the topic).
Over the two days, different aspects of the question
‘upstream’ (pathophysiology and biology) and ‘down-
stream’ (treatment and outcome assessment) were focused
on.
The first day began with an examination of the ‘Patho-
physiological basis of COPD as a systemic disease’ with
Paolo Palange (Rome, Italy) presenting the pro-systemic
side and Andrea Rossi (Bergamo, Italy) the non-
systemic side. Palange, on the basis of evidence of chronic
systemic inflammation and more recent observations of
increased levels of endothelial cell apoptosis and reduced
levels of angiogenetic factors (e.g. VEGF) in the lung in
response to cigarette smoking and to oxidative stress,
suggesting that emphysema may be a vascular disease with
possibly an autoimmune component, retained that COPD, in
particular emphysema, could be considered as ‘‘a disease
with a significant systemic component’’ if not a ‘‘systemic
disease’’ per se.10 Rossi argued that inflammation in the
airways is probably the starting point of COPD and that
airflow limitation is a central element, and to some extent
the bridge, connecting biological defects to the complex
clinical phenotypes. Without doubt, airflow limitation is
a key mechanism determining dyspnea, progressive
disability, and ventilatory failure in patients with COPD.11
These presentations were followed by an examination of
the role of inflammation in COPD (‘COPD and systemic
inflammation: myth or reality?’), with William MacNee
(Edinburgh, UK) sustaining the case for, and Giuseppe Di
Maria (Catania, Italy) challenging the systemic argument.
MacNee sustained that systemic inflammation is likely
a major contributor to the pathobiology of the extrap-
ulmonary effects of COPD including skeletal muscle atrophy
and dysfunction and cardiovascular disease.12 Though the
mechanism is still unknown, it may relate to spill over from
the lungs to the systemic circulation or to genetic or
constitutional factors which predispose individuals to COPD
or to either systemic or pulmonary inflammation. Other
potential origins of systemic inflammation in COPD include
cigarette smoking, lung hyperinflation, tissue hypoxia,
skeletal muscle dysfunction and a response of the bone
marrow. Di Maria agreed that the causes of the systemic
1272 C.F. Donner, L. Bjermerconsequences are complex and poorly understood, but
maintained that they have been unduly attributed to
a putative ‘‘systemic inflammation’’ along with the oxida-
tive damage suffered by COPD patients. Mankind, he
concluded, has an innate need to create myths and to trust
in them, but undoubted opinions, even those based on
circumstantial evidence, are not a sure way to reach the
truth.
The focus then shifted to biological aspects, looking at
the evidence for biomarkers: first in stable COPD
(‘Biomarkers of systemic involvement in stable COPD: do
they exist?’) with Claudio M. Sanguinetti (Rome, Italy)
presenting (on behalf of Emiel Wouters) the case for, and
Giorgio W. Canonica (Genoa, Italy) the case against. San-
guinetti emphasized the need for biomarkers in COPD
research to better diagnose and to assess phenotype,
severity, and the effects of treatment. C-reactive protein
(CRP), tumor necrosis factor (TNF)-a, fibrinogen, and
circulating leukocytes are some of the markers that have
been investigated.13 What is not known is whether these
markers predict the progression of the disease, which
would make them useful as a clinical biomarker. Canonica
underlined that the inflammatory cascade implicated in
lung parenchyma destruction may spread to a systemic
level and induce further organ damage. However, it should
be borne in mind that elderly subjects present comorbid-
ities, and COPD concomitant diseases can be the cause of
the increased biomarkers in these patients. No doubts exist
about the presence of systemic inflammatory markers and
their organ-related effects in COPD, but further investiga-
tion is required to clarify the source and meaning of the
inflammatory process.14,15,16,17
The role of exacerbations is central in COPD as a major
factor related to disease deterioration and has a severe
negative impact on quality of life. The systemic aspect of
exacerbations was discussed in this context (‘Biomarkers of
systemic involvement in acute exacerbations of COPD e do
they exist?’) with John Hurst (London, UK) putting the case
for, and Antonio Anzueto (San Antonio, USA) the case
against. Hurst argued that COPD exacerbations are now
recognized as an important outcome measure in COPD but
they are heterogeneous events and also seasonal in their
occurrence, i.e. often triggered by respiratory viral infec-
tions. There is evidence that during a COPD exacerbation
the systemic inflammatory response is related to the airway
response e hence a systemic marker should reflect the
pathophysiological changes associated with the exacerba-
tion. However, there is an urgent need for novel markers of
exacerbation that can reflect both the onset of the exac-
erbation and the recovery period. Anzueto cited recent
reports characterizing the upregulation of pro-inflamma-
tory cytokines in the intercostals and other respiratory
muscles. So, in theory, anti-inflammatory treatment should
contribute to the reduction of exacerbations. Clinical
studies that involve the use of long-acting bronchodilators,
with or without inhaled corticosteroids, or surgical inter-
ventions such as lung volume reduction surgery (LVRS) have
been associated with significant reduction in COPD exac-
erbation. The physiological consequences of airway
obstruction, mainly hyperinflation, may be the main
precipitating factor of the systemic inflammatory response
seen in these patients.18The second day was devoted mainly to the clinical and
treatment aspects (‘Science at the bedside’) starting with
a Rationale (‘Is COPD a respiratory disease with prominent
systemic implications or a systemic condition with pulmo-
nary symptoms?’) presented by Bartolome Celli (Boston,
USA) and a Case Report by Richard ZuWallack (Hartford,
USA). Celli outlined the two different views relating the
associations between COPD and its comorbidities: i)
systemic ‘‘spillage’’ of the inflammatory and reparatory
events occurs in the lungs, with the disease remaining at
the center of the process; ii) pulmonary manifestations of
COPD are an expression of a ‘‘systemic’’ inflammatory state
with multiple organ compromise. Both views have merit but
imply different conceptual approaches with important
therapeutic consequences. In the former, the aims of
therapy are primarily centered in the lungs whereas in the
latter, the center of therapy should be shifted to the
primary source. ZuWallack then presented the case of a 75-
year-old woman with a diagnosis of COPD since 1995, and
concluded that systemic inflammation is clearly present in
COPD and that this contributes directly to the lung disease
and its comorbidities. Whether this process is viewed as
a systemic ‘spill-over’ from inflammation in the lung or is
a primarily systemic process with the lung as the portal is,
in reality, more semantic than pragmatic.
The view of whether COPD is a mainly organ centered
or a more systemic disease impacts on how to treat the
COPD patients. This was discussed as ‘Approach to COPD:
respiratory or systemic treatment’ with Richard Casaburi
(Torrance, USA) arguing for the respiratory approach and
Leo Fabbri (Modena, Italy) for the systemic approach.
Casaburi stated that, while substantial attention has been
placed on systemic inflammation in COPD, the increased
levels of circulating inflammatory mediators reported in
moderateesevere COPD are small and of questionable
importance. It has been difficult to predict, on the basis of
increases in circulating inflammatory mediators, patient
characteristics that are likely to be important (and,
therefore, to constitute a good therapeutic target) in the
individual patient. Similarly, muscle dysfunction has in
part been ascribed to inflammation and apoptosis but the
variability of findings among subjects makes this a difficult
therapeutic target. Fabbri argued that the diagnosis,
assessment of severity and treatment of COPD may be
greatly affected by the presence of comorbid conditions.
Lung function measurement, non-invasive assessment of
left ventricular function (e.g. echocardiography and brain
natriuretic peptide) and/or glycaemia may be useful to
identify these comorbidities. Much can be learnt from
other chronic conditions, and the therapeutic approach to
comorbidities can have a positive effect on COPD. Simi-
larly, smoking prevention and cessation, weight control
and diet, and exercise and rehabilitation potentially affect
not only COPD but also its comorbidities.
Finally, clinical practice guidelines and their relevance in
the light of this current debate came under scrutiny
(‘Guidelines and clinical practice: myth or reality?’) with
Marc Miravitlles (Barcelona, Spain) arguing for the ‘myth’
side and Steve Rennard (Omaha, USA) for the ‘reality’ side.
For Miravitlles, guidelines are a ‘‘myth’’ due to the
discrepancy between the guidelines’ definition of COPD and
that ‘‘universally’’ accepted in clinical practice. Until we
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be in clinical practice, sterile controversies will continue on
the efficacy of different treatments in the ‘‘so-called’’
COPD. For Rennard, guidelines are ‘‘real’’ in that they do
exist and provide a framework for the clinician when appli-
cation of a diagnostic or therapeutic modality is uncertain.
They can inform clinicians in making their judgments and,
therefore, help optimize diagnosis and therapy.Is COPD a systemic disease or a syndrome?
Nikos Siafakas (Heraklion, Greece) in his summing up of the
meeting stated that much energy and attention during
the two-day Seminar had been focused on how to define the
term ‘systemic’. As to whether COPD is a systemic disease
or not, during the Seminar ‘systemic’ had been referred to
in various ways as: a) systemic inflammation; b) systemic
manifestations; c) systemic consequences; d) comorbid-
ities; or e) multi-organ disease.
Comorbidities are often confused with systemic effects:
the question is whether they are simply an overlap or imply
some sort of cause and effect. For instance, is there some
event occurring in the lung which has a ‘‘spill-over’’ of
mediators or whatever that causes a systemic manifesta-
tion such as cachexia? There is no strong evidence in this
direction. In cardiology, cachexia is defined as a systemic
effect of chronic heart failure; in nephrology, cachexia is
defined as a systemic effect of renal failure; and in
oncology, it is defined as a systemic effect. Hence cachexia
could be seen as one of the manisfestations that acts along
with the lung damage. So you have a mechanism e still to
be defined e that is simultaneously causing (in different
proportions) tissue abnormalities in different organs.
The large majority, however, expressed their under-
standing of COPD as a disease having ‘systemic conse-
quences’ or ‘systemic manifestations’. Do these systemic
manifestations of COPD imply a multi-organ disease like
scleroderma or lupus or some more centrogenic disease
followed by effects in sequence?
A disease, in fact, can be multi-organ without being
systemic. The difference between multi-organ disease and
a disease that has systemic manifestations or consequences
could be exemplified by polycystic kidney disease (a simple
gene manifestation associated with kidney disease and also
with brain aneurysms, so it affects more than one organ,
and is manifested in more than one place) as opposed to
scleroderma or sarcoidosis or even COPD as a diffuse
disease (in which multiple organs are targets of the disease
process). COPD does affect the entirety of the individual, or
close to it, and in this sense is, arguably, systemic.
Instead of differentiating between different kinds of
COPD, we should rather focus on the differences between
mild vs. moderate vs. more severe COPD since, as Emox
pathology shows, as COPD progresses the pathology itself
may change, as also its consequences. Hence there is an
urgent need for phenotyping of the disease to better
understand what COPD is.19 The disease process, in fact,
starts much earlier, long before FEV1 enters into the picture
in a meaningful way, but we do not yet have the test to
detect it while in its silent phase. Nevertheless, when it
does manifest in terms of sputum, dyspnea, from that pointonwards we can try to answer the question if COPD affects
other organs or other systems at the same time, or whether
it first manifests in the lung and then in other systems.
The term ‘‘systemic’’, while it could be applicable to
COPD, is very confounding as we use this term for diseases
which have a common background (either pathogenetic or
etiologic). In the context of COPD, does it refer to the same
pathology in different organs? So far we have no proof that
the same pathology, e.g. emphysema, is found in the heart
e we don’t have ‘emphysematous heart’. So the manifes-
tations in COPD are not a case of a similar pathology
manifesting in different organs.
The term ‘systemic’ is usually used in connection with
COPD in relation to hypoxia or to the muscle component.
Hypoxia, however, is not specific to COPD e it can also be
causedby interstitialdisorders,e.g. at theendoffibrosis there
is persistent hypoxia which can have consequences in other
organs. So it is necessary to think in terms of the mechanism
before deciding our answer to this question.20,21,22What are the mechanisms that link the lung to
the systemic effects?
Is the inflammation in COPD simply coincidental or is it
something more fundamental? Is there some sort of
inflammation or oxidative stress that causes all these
systemic effects of COPD, or has it got to do with the
autoimmune system, or with aging? In other words, is there
some sort of interaction going on? Could there be a systemic
phenotype (i.e. are some people born to be inflammatory?)
so that, whatever triggers it, you get an inflammatory
response (e.g. the bone marrow response) that influences
back on the lung condition? Answering this is important in
determining whether to target the lung or something else.
In regard to comorbidities, atherosclerosis and problems in
the coronary arteries are particularly present in patients
with emphysema, while other COPD patients are less
prone.23 So there exist different patient subsets and we
should be cautious about lumping all patients together
when talking about comorbidities.What distinguishes the term ‘consequence’
from ‘manifestation’?
A manifestation is something that you can measure with
a biomarker, e.g. in blood, but if it has no clinical impact
and there are no consequences, then it would be insuffi-
cient to qualify it as a disease. The pro-systemic supporters
retained that what makes COPD a systemic disease are its
systemic consequences (e.g. if hypoxia had no conse-
quences other than you could measure it, that would not be
sufficient to label COPD a systemic disease).
Most of the systemic consequences of COPD are, in fact,
rather triviale people who are short of breath sit around and
do nothing and their muscles have disuse atrophy. That is
a trivial consequence, but not a systemic disease. On the
other hand, the excess deaths from cardiovascular disease
(CVD) e that’s not strictly a consequence of just how the
lungs are running. Secondly, there are some subtle mani-
festations, e.g. in muscle dysfunction there is a type 2 fibre
1274 C.F. Donner, L. Bjermerpredominance. Why is that? It is something specific to COPD.
And the third thing is cachexia e clearly it occurs only in
a small minority of patients, the body just shuts down, the
patient’s going to die, and a whole bunch of organs change
and that truly is a systemic manifestation and in COPD it is
primarily a manifestation of COPD. So the answer depends.
It was agreed that, while there is a small (but significant
from the point of view of mortality) phenotype of COPD
that can manifest or have a lot of systemic consequences,
this really does not justify labelling COPD as ‘systemic’ by
definition because a definition has to cover all the cases. Do
all COPD patients have systemic disease or systemic
consequences? Most thought not.
On the question of phenotypes, three possible pathways
were hypothesized for COPD:
- Phenotype A: Causeþ genes type 1/ COPDþ genes
type 2/ CVD/osteoporosis/muscle wasting
- Phenotype B: Causeþ genes type 3/ COPD together
with CVD and/or osteoporosis and/or muscle wasting
- Phenotype C: COPD/ COPD
In scenario A, if the subject is susceptible to the cause,
i.e. smoking, due to genetic predisposition (genes type1),
COPD will develop. Then, as the disease progresses, in the
presence of other genes (type 2), this may lead to the
development of other diseases like CVD or osteoporosis. In
scenario B, in patients with a different set of genes (type 3),
the cause may determine COPD together with other diseases
at the same time, i.e. smoking in combination with genotype 3
will lead to both COPD and CVD. In scenario C, we have
a phenotype by which the cause leads to COPD alone without
any progression to other diseases. All these pathogenetic
relationships to systemic disease can occur and we see all
threeof thesephenotypes inclinicalpractice.The importance
of geneeenvironment interaction was stressed, in that
data now show that the same gene, according to different
exposures, can alter. For instance, you have some susceptible
genes to start COPD and, due to oxidative stress from
continued smoking, you damage your lung and cannot repair it
so you have somatic alterations that may be due to different
phenotyping.
The conclusions were that:
 COPD is not a systemic disease but severe COPD has
a number of systemic consequences
 there is no ideal biomarker to indicate that COPD is
a systemic disease
 phenotyping COPD is important: COPD is not one
disease but has many different phenotypes
 genes play a fundamental determining role
It may actually not be in your genes yet, but since you can
acquire somatic cell mutations, and since cigarette smoking
(environment) is notorious for causing somatic cell mutations
in your lung, it may come to be in your genes. While there are
some examples of disease developing in the absence of
obvious environmental inputs (e.g. in genetic models of aging
both in mice and man emphysema has been shown to develop)
the fact is we all breathe air and what’s in the air, so every-
body is exposed in that sense. For those patients with COPDwho never smoked it is possible that passive smoking exposes
to the risk, so genes plus a ‘‘normal’’ life should be enough to
account for COPD pathogenesis.
While the Seminar did not reach a final evidence-based
conclusion, the general consensus that emerged, based on
the still limited evidence available, was that COPD begins
as a local inflammation in the lungs and this leads e
through differentiated pathways still to be clarified e to
systemic consequences. The Seminar represented a starting
point for a new era in clinical and experimental research,
based on the excellent quality of the discussions held over
the two days with the experts gathered in this unforget-
table setting of Venice.
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